• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Catalyst Biosciences Inc. (Amendment)

    1/24/24 5:11:14 PM ET
    $CBIO
    Get the next $CBIO alert in real time by email
    SC 13D/A 1 ef20019625_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D/A
    Under the Securities Exchange Act of 1934
    (Amendment No. 4)*

    Gyre Therapeutics, Inc.
    (Name of Issuer)

    Common Stock, par value $0.001
    (Title of Class of Securities)

    403783 103
    (CUSIP Number)

    Ying Luo, Ph.D.
    GNI Group Ltd.
    Nihonbashi-Honcho YS Bldg. 3rd Floor
    2-2-2 Nihonbashi-Honcho, Chuo-ku,
    103-0023 Tokyo, Japan
    +81-3-6214-3600
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    January 22, 2024
    (Date of Event Which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 403783 103
    1
    NAMES OF REPORTING PERSONS
     
     
    GNI USA, Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    73,313,885(1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    73,313,885(1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    73,313,885(1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    85.34%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     
    (1) Consists of: (i) 417,768 shares of Common Stock (defined below), previously issued to GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (“GNI Japan”), and GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (“GNI Hong Kong”), in a private issuance pursuant to that certain Asset Purchase Agreement, dated December 26, 2022, as amended on March 29, 2023 (the “F351 Agreement”) and transferred to GNI USA, Inc., a Delaware corporation (“GNI USA”) in a reorganization among GNI Japan related parties (the “Reorganization”), (ii) 8,226,666 shares of Common Stock issued upon conversion of 12,340 shares of Convertible Preferred Stock (defined below), which were previously issued to GNI Japan and GNI Hong Kong in a private issuance pursuant to the F351 Agreement and transferred to GNI USA in the Reorganization, (iii) 63,588,119 shares of Common Stock issued to GNI USA pursuant to that certain Business Combination Agreement, dated as of December 26, 2022 and as amended on March 29, 2023 and August 30, 2023 (the “Business Combination Agreement”), (iv) 540,666 shares of Common Stock issued upon conversion of 811 shares of Convertible Preferred Stock, which were issued to GNI USA in a private placement (the “Private Placement”) pursuant to that certain Securities Purchase Agreement, dated October 27, 2023 and (v) 540,666 shares of Common Stock issuable upon conversion of 811 shares of Convertible Preferred Stock underlying the warrants issued to GNI USA in the Private Placement.

    (2) The ownership percentage in this schedule is based upon an aggregate of (i) 85,371,629 shares of Common Stock issued and outstanding as of January 23, 2024 and (ii) 540,666 shares of Common Stock issuable upon conversion of shares of Convertible Preferred Stock issuable upon conversions of warrants to purchase shares of Convertible Preferred Stock that are beneficially owned by GNI USA.


    CUSIP No. 403783 103
    1
    NAMES OF REPORTING PERSONS
     
     
    GNI Group Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Japan
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    73,313,885(1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    73,313,885(1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    73,313,885(1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    85.34%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     
    (1) Consists of: (i) 417,768 shares of Common Stock, previously issued to GNI Japan and GNI Hong Kong in a private issuance pursuant to the F351 Agreement and transferred to GNI USA in the Reorganization, (ii) 8,226,666 shares of Common Stock issued upon conversion of 12,340 shares of Convertible Preferred Stock, which were previously issued to GNI Japan and GNI Hong Kong in a private issuance pursuant to the F351 Agreement and transferred to GNI USA in the Reorganization, (iii) 63,588,119 shares of Common Stock issued to GNI USA pursuant to the Business Combination Agreement, (iv) 540,666 shares of Common Stock issued upon conversion of 811 shares of Convertible Preferred Stock, which were issued to GNI USA in the Private Placement and (v) 540,666 shares of Common Stock issuable upon conversion of 811 shares of Convertible Preferred Stock underlying the warrants issued to GNI USA in the Private Placement.

    (2) The ownership percentage in this schedule is based upon an aggregate of (i) 85,371,629 shares of Common Stock issued and outstanding as of January 23, 2024 and (ii) 540,666 shares of Common Stock issuable upon conversion of shares of Convertible Preferred Stock issuable upon conversions of warrants to purchase shares of Convertible Preferred Stock that are beneficially owned by GNI USA.


    Explanatory Note

    This Amendment No. 4 to the statement on Schedule 13D (this “Amendment”) relates to shares of common stock, $0.001 par value (“Common Stock”) of Gyre Therapeutics, Inc., a Delaware corporation (formerly known as Catalyst Biosciences, Inc., the “Issuer”), and amends the statement on Schedule 13D filed on January 5, 2023, as amended by Amendment No. 1 filed on October 31, 2023, Amendment No. 2 filed on November 1, 2023 and Amendment No. 3 filed on November 27, 2023 (the “Original Filing”), by the Reporting Persons. Except as otherwise provided herein, each Item of the Original Filing remains unchanged. Capitalized terms used and not defined in this Amendment have the meanings set forth in the Original Filing.

    Item 4.
    Purpose of Transaction.

    The section entitled “Convertible Preferred Stock Conversion” set forth in Item 4 of Amendment No. 3 to the Original Filing is replaced in its entirety with the following:

    Convertible Preferred Stock Conversion

    On November 22, 2023, GNI USA delivered to the Issuer a Notice of Stock Conversion, pursuant to which GNI USA irrevocably elected to convert 13,151 shares of Series X Convertible Preferred Stock, par value $0.001 per share, of the Issuer (“Convertible Preferred Stock”) into 8,767,333 shares of Common Stock. On January 23, 2024, subject to the terms and conditions of the Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, as amended, 8,767,333 shares of Common Stock were issued to GNI USA upon such conversion.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: January 24, 2024
    GNI Group Ltd.
       
     
    /s/ Thomas Eastling
     
    By:
    Thomas Eastling
     
    Its:
    Attorney-in-fact
       
    Dated: January 24, 2024
    GNI USA, Inc.
       
     
    /s/ Thomas Eastling
     
    By:
    Thomas Eastling
     
    Its:
    Director



    Get the next $CBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBIO

    DatePrice TargetRatingAnalyst
    11/15/2021Outperform → Market Perform
    Raymond James
    8/6/2021$19.00 → $18.00Outperform
    Raymond James
    More analyst ratings

    $CBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Luo Ying acquired 2,840,376 shares (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/22/23 7:55:53 PM ET
      $CBIO
    • SEC Form 4 filed by Ye Weiguo

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/22/23 7:49:12 PM ET
      $CBIO
    • SEC Form 4 filed by Ma Songjiang

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      11/22/23 7:40:34 PM ET
      $CBIO

    $CBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Catalyst Biosciences downgraded by Raymond James

      Raymond James downgraded Catalyst Biosciences from Outperform to Market Perform

      11/15/21 4:49:07 AM ET
      $CBIO
    • Raymond James reiterated coverage on Catalyst Biosciences with a new price target

      Raymond James reiterated coverage of Catalyst Biosciences with a rating of Outperform and set a new price target of $18.00 from $19.00 previously

      8/6/21 12:08:01 PM ET
      $CBIO
    • Stephens resumed coverage on Catalyst Biosciences with a new price target

      Stephens resumed coverage of Catalyst Biosciences with a rating of Overweight and set a new price target of $19.00 from $18.00 previously

      4/29/21 1:31:07 PM ET
      $CBIO

    $CBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

      Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001 On Track to Submit IND Application for CR-001 in Fourth Quarter of 2025 with Proof-of-Concept Clinical Data Expected in Second Half of 2026 Shares to Begin Trading on Nasdaq Under Ticker Symbol "CBIO" Today, June 16 WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company"), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the completion of its previously announced merger with GlycoMimetics, Inc. ("GlycoMimetics"). The com

      6/16/25 7:00:00 AM ET
      $CBIO
    • Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

      EMERYVILLE, Calif., Dec. 15, 2023 /PRNewswire/ -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, Totus co-founder, founding CEO, and CSO, will transition into a new role as CSO and Head of R&D, where he will continue to oversee the company's platform, programs, and data. "We are thrilled by Nassim's arrival," said DCVC Bio Managing Pa

      12/15/23 9:04:00 AM ET
      $CBIO
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

      The combined company will operate as "Gyre Therapeutics, Inc." with its common stock traded on Nasdaq under trading symbol "GYRE" effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst") today announced completion of the business combination with GNI Group Ltd. and related entities. Catalyst received stockholder approval for all proposals necessary to complete the business combination at a special meeting of stockholders held on August 29, 2023. Catalyst effected a name change and a reverse stock split of Catalyst's common stock immediately prior to the closing of the business combination. The combined company w

      10/30/23 12:00:00 PM ET
      $CBIO

    $CBIO
    SEC Filings

    See more
    • Catalyst Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      2/14/24 5:16:03 PM ET
      $CBIO
    • Catalyst Biosciences Inc. filed SEC Form 8-K: Leadership Update, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (Amendment)

      8-K/A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      1/19/24 4:05:30 PM ET
      $CBIO
    • Catalyst Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (Amendment)

      8-K/A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      1/12/24 4:01:35 PM ET
      $CBIO